You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 10, 2026

Changes in Nutrition Labeling Requirements in Indonesia

Subscribe to Updates

On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels.

The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period.

Implementation of the Nutri-Level Labeling System

To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging.

The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content.

For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml.

Minimum Vitamin and Mineral Content Required for Declaration

BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING).

Vitamins or minerals may only be declared if they are present at a level of at least 5% of the recommended dietary allowance (RDA) per serving, per 100 g, per 100 ml, or per package, in accordance with the inclusion of the ING table, except for processed foods that declare vitamins or minerals claims in accordance with certain laws and regulations. This represents a significant change from the previous regime under the now-revoked BPOM Regulation No. 26 of 2021, under which vitamins and minerals could be declared when present at a level of at least 2% of the RDA per serving.

Revised Serving Size Requirements

While serving size declarations were already required under BPOM Regulation No. 26 of 2021, BPOM Regulation No. 10 of 2026 introduces additional technical guidance on serving-size determination and presentation. The new regulation expressly requires serving sizes to be rounded to the nearest half-unit, providing a standardized approach to serving-size calculations across product categories. An exception applies to products classified under food category 11.6 (sweeteners, including table-top sweeteners and high-intensity sweeteners), which may require businesses to review and, where necessary, update their existing nutrition labeling.

In addition, an appendix to Regulation No. 10 of 2026 sets out updated serving-size references for a wide range of food categories. As a result, food business operators should review the revised category-specific serving-size references to determine whether their existing nutrition information tables, nutrient calculations, and serving-size declarations remain compliant under the new framework. Although serving-size requirements were already regulated under BPOM Regulation No. 26 of 2021, the 2026 regulation provides greater technical detail and updated references that may necessitate label revisions for certain products.

Updated Nutrient Reference Values

BPOM Regulation No. 10 of 2026 updates the nutrient reference values previously set forth in BPOM Regulation No. 9 of 2016 to correspond with the current development of scientific knowledge in health. Several reference values have been revised from those in BPOM Regulation No. 9 of 2016 (e.g., for total fat, vitamin B1, vitamin B2, vitamin B12, magnesium, potassium, and various other vitamins and minerals). As these values are used to calculate the percentage of RDA displayed in nutrition information tables, the revisions may affect the nutrient percentage calculations currently appearing on product labels.

The regulation also introduces updated nutrient reference methodologies and conversion factors. In particular, vitamin B3 may now be expressed in niacin equivalents (NE), folate may be expressed in dietary folate equivalents (DFE), and revised conversion factors have been adopted for vitamins A, D, and E. These changes are intended to align nutrition labeling requirements with current nutritional science and may require food business operators to reassess existing nutrient declarations and label calculations.

Updated Nutritional Value Information Table Formats

BPOM Regulation No. 10 of 2026 updates the standardized formats for the nutritional value information (ING) table. The regulation continues to allow both vertical and horizontal formats and now provides clearer templates for use on product labels.

For horizontal presentation, businesses may use either a three-column tabular format, which provides more space for displaying nutrient information and additional vitamins or minerals, or a two-column tabular format, which offers a simplified layout suitable for products with limited label space.

 

Three-column per-serving tabular format

 

Two-column per-serving tabular format

 

Three-column per-package tabular format

 

Two-column per-package tabular format

 

BPOM Regulation No. 10 of 2026 also introduces specific flexibility for micro-enterprises regarding the ING table. If analytical results are unavailable and the value of a processed food nutrient has not yet been established by the head of BPOM, the values in the ING table should be declared based on calculation results. The procedure for calculating the nutrient content for processed foods produced by micro-enterprises was established by the head of BPOM in 2026 and involves mostly traditional Indonesian food products.

Transition Period

BPOM Regulation No. 10 of 2026 provides a 24-month transition period to facilitate compliance with the new requirements, so processed foods that had already obtained distribution permits before the regulation entered into force, as well as products that were undergoing registration at that time, must be brought into compliance with the new regulation by June 17, 2028. Similar transitional provisions apply to the implementation of Nutri-Level labeling requirements for affected beverage products. As a result, food business operators are afforded additional time to review product portfolios, update nutritional information, and revise product labels where necessary.

Business Impact

The new regulation will require many food and beverage businesses to review their existing nutrition labeling practices in order to comply with the new requirements. In particular, companies should assess the impact of the revised nutrient reference values, updated serving-size requirements, and Nutri-Level labeling requirements on their products.

The Nutri-Level requirements will be especially relevant for beverage manufacturers. Businesses should therefore begin evaluating their product portfolios and preparing any necessary label updates to ensure compliance before the expiry of the 24-month transition period.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

January 8, 2021
Across the globe, the demand for COVID-19 vaccinations has been understandably high, with many regulatory authorities (e.g., U.S. Food and Drug Administration, Medicines & Healthcare Products Regulatory Agency in the U.K., European Medicine Agency, Swissmedic, etc.) issuing emergency use authorizations for COVID-19 vaccines. Similarly, the Thai Food and Drug Administration (Thai FDA) has published the Notification Re: Conditional Approval for Emergency Use of Medical Products, which allows drug importers to register COVID-19 vaccines under the conditional approval scheme.  While as of the date of this article, the Thai FDA has yet to authorize any COVID-19 vaccines, this should follow shortly as clinical trials are completed and government procurement negotiations progress. Under the notification, it appears that the channel of distribution of a COVID-19 vaccine under the conditional approval scheme would be strictly controlled by the Thai FDA. This channel includes the vaccine’s distribution to relevant government agencies (e.g., Department of Disease Control of Thailand and public hospitals specified by the Thai FDA). However, questions have been raised regarding which private hospitals would be included in the distribution list and how the Thai FDA would distribute the vaccine to private hospitals. This confusion over the role of private hospitals was seen recently when one private hospital advertised that it could secure the COVID-19 vaccine from one developer whose product had already been approved elsewhere, until the Thai FDA then stepped in and claimed that the advertisement violated the Drug Act. The Thai FDA notification also enumerates several essential criteria that must be fulfilled in seeking approval for a COVID-19 vaccine, including the following: The available scientific data must substantiate both the efficacy and safety of vaccine. Further, the risk-benefit analysis must indicate that the medicine’s benefits outweigh its risks. A risk management plan, including risk minimization measures, must be submitted.
Read More
January 8, 2021
At a meeting on December 21, 2020, the Thai Board of Investment (BOI) approved a series of stimulus packages aimed at encouraging local and foreign investment, as the government seeks to boost Thailand’s economic recovery from the COVID-19 pandemic. The additional investment incentives, which will be promoted by the BOI in the upcoming year, include a number of sector- and project-specific stimulus measures.   Additional Tax Incentives for Large-Scale Projects Projects in target industries with investment of at least THB 1 billion (approx. USD 33 million) over a 12-month period, starting from the issuance of the BOI promotion certificate, will be entitled to an additional 50% corporate income tax (CIT) deduction for a period of five years, calculated on top of the standard 5–8 year CIT exemptions offered under the normal BOI tax-incentive scheme. To obtain this special tax incentive, eligible projects may apply to the BOI from January 4 to December 30, 2021.   Stimulus Package for Digital Economy and Software Industry Projects that support digital technology adoption, such as software integration, artificial intelligence, machine learning, or big data analytics, may benefit from 50% CIT exemptions on profits generated from their existing BOI projects for an additional three years. Applications for the exemption must be submitted by the end of 2022.   Application Deadline Extensions for Special Economic Zones and Five Southern Provinces Measures relating to special economic zones cover more than 300 investment promotion categories, with both tax and non-tax incentives, including an additional tax incentive for target industries such as textiles, agriculture, home furniture, jewelry, and others. These incentives are available to projects located in the border areas of Thailand (i.e., the 10 special economic zones in the provinces of Chiang Rai, Kanchanaburi, Mukdahan, Nakhon Phanom, Narathiwat, Nong Khai, Sa Kaeo, Songkhla, Tak, and Trat), with the
Read More
December 21, 2020
As we continue to await the Thai Food and Drug Administration (TFDA)’s promulgation of its medical cannabis application guidelines, the Thai Ministry of Public Health (TMoPH) has helpfully issued several notifications to further clarify the 2019 amendment to the Narcotics Act that initially paved the way for cannabis liberalization in the kingdom. Cannabis (both marijuana and hemp) has been classified as a Category 5 Narcotic since the enactment of the Narcotics Act in 1979. All activities related to the plants and their derivatives had been strictly restricted until the recent rise of the cannabis legalization movement, which began in Thailand with an amendment to the Narcotics Act in February 2019 to legalize medical marijuana. The Thai government has since been working to reclassify cannabis products and lay out the regulatory pathways to accommodate these new “economic plants.” A notification in August 2019 further carved modern drugs, cosmeceuticals, nutraceuticals, cosmetics, and food containing hemp or a certain amount of CBD out of the scope of Narcotics Act. The most recent TMoPH Notification was published in the Government Gazette on December 14, 2020, and has expanded the delisting of cannabis from the Narcotics Act to include nearly all parts of the cannabis plant, as set out below. Type of Plant Detailed Components Marijuana (plants in the cannabis family) Stalks, stems, fibers, branches, roots, leaves without the tip and inflorescence, extracts comprising CBD with less than 0.2% THC by weight. Hemp Stalks, stems, fibers, branches, roots, seeds, seed oils, seed extracts, leaves without the tip and inflorescence, extracts comprising CBD with less than 0.2% THC by weight, and residues from extraction with less than 0.2% THC by weight. The Narcotics Act and its notifications must be reviewed carefully by anyone seeking to take part in his industry, and items that are conspicuous
Read More